Literature DB >> 24898083

Histone deacetylase inhibitors and cell death.

Jing Zhang1, Qing Zhong.   

Abstract

Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin remodeling and have crucial roles in numerous biological processes, largely through their repressive influence on transcription. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression. Recently, HDACs have gained growing attention as HDAC-inhibiting compounds are being developed as promising cancer therapeutics. Histone deacetylase inhibitors (HDACi) have been shown to induce differentiation, cell cycle arrest, apoptosis, autophagy and necrosis in a variety of transformed cell lines. In this review, we mainly discuss how HDACi may elicit a therapeutic response to human cancers through different cell death pathways, in particular, apoptosis and autophagy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24898083      PMCID: PMC4414051          DOI: 10.1007/s00018-014-1656-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  226 in total

1.  Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression.

Authors:  Rebecca L VanOosten; Jill M Moore; Bahri Karacay; Thomas S Griffith
Journal:  Cancer Biol Ther       Date:  2005-10-13       Impact factor: 4.742

2.  Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins.

Authors:  A M Verhagen; P G Ekert; M Pakusch; J Silke; L M Connolly; G E Reid; R L Moritz; R J Simpson; D L Vaux
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

3.  Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death.

Authors:  Noor Gammoh; Du Lam; Cindy Puente; Ian Ganley; Paul A Marks; Xuejun Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

4.  Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.

Authors:  Sean C Dowdy; Shujuan Jiang; X Clare Zhou; Xiaonan Hou; Fan Jin; Karl C Podratz; Shi-Wen Jiang
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

5.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

6.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.

Authors:  Ping Zhu; Elke Martin; Jörg Mengwasser; Peter Schlag; Klaus-Peter Janssen; Martin Göttlicher
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

7.  Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state.

Authors:  Marcella Fulco; R Louis Schiltz; Simona Iezzi; M Todd King; Po Zhao; Yoshihiro Kashiwaya; Eric Hoffman; Richard L Veech; Vittorio Sartorelli
Journal:  Mol Cell       Date:  2003-07       Impact factor: 17.970

8.  Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.

Authors:  Giuseppe Iacomino; Maria Cristina Medici; Gian Luigi Russo
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

9.  Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

Authors:  Hirotaka Osada; Yoshio Tatematsu; Hiroko Saito; Yasushi Yatabe; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

10.  Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation.

Authors:  Young Sik Cho; Sreerupa Challa; David Moquin; Ryan Genga; Tathagat Dutta Ray; Melissa Guildford; Francis Ka-Ming Chan
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

View more
  65 in total

Review 1.  Selective class IIa HDAC inhibitors: myth or reality.

Authors:  Eros Di Giorgio; Enrico Gagliostro; Claudio Brancolini
Journal:  Cell Mol Life Sci       Date:  2014-09-05       Impact factor: 9.261

2.  Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.

Authors:  Hye-Young Min; Su-Chan Lee; Jong Kyu Woo; Hyun Jin Jung; Kwan Hee Park; Hae Min Jeong; Seung Yeob Hyun; Jaebeom Cho; Wooin Lee; Ji Eun Park; So Jung Kwon; Hyo-Jong Lee; Xiao Ni; Young Kee Shin; Faye M Johnson; Madeleine Duvic; Ho-Young Lee
Journal:  Clin Cancer Res       Date:  2016-08-31       Impact factor: 12.531

3.  BAY 87-2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3β activation.

Authors:  Yang-Ling Li; Ming-Jun Rao; Ning-Yu Zhang; Lin-Wen Wu; Neng-Ming Lin; Chong Zhang
Journal:  Exp Ther Med       Date:  2019-04-18       Impact factor: 2.447

4.  Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.

Authors:  Juliana K Ariffin; Kaustav das Gupta; Ronan Kapetanovic; Abishek Iyer; Robert C Reid; David P Fairlie; Matthew J Sweet
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors.

Authors:  Jianbin Zhang; Jigang Wang; Zhihong Zhou; Jung-Eun Park; Liming Wang; Shuai Wu; Xin Sun; Liqin Lu; Tianru Wang; Qingsong Lin; Siu Kwan Sze; Dongsheng Huang; Han-Ming Shen
Journal:  Autophagy       Date:  2018-07-30       Impact factor: 16.016

Review 6.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

7.  Acetylation of p53 Protein at Lysine 120 Up-regulates Apaf-1 Protein and Sensitizes the Mitochondrial Apoptotic Pathway.

Authors:  Tao Yun; Kaiwen Yu; ShuangShuang Yang; Yifan Cui; Zixi Wang; Huiyu Ren; She Chen; Lin Li; Xiaoyun Liu; Min Fang; Xuejun Jiang
Journal:  J Biol Chem       Date:  2016-02-05       Impact factor: 5.157

8.  Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death.

Authors:  U Beyer; S K Krönung; A Leha; L Walter; M Dobbelstein
Journal:  Cell Death Differ       Date:  2015-05-29       Impact factor: 15.828

Review 9.  Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Nikolaos Charalampakis; Leon Naar; Maria Ioannidi; Diamantis Tsilimigras; Maria Sotiropoulou; Dimitrios Moris; Pantelis Vassiliu; Evangelos Felekouras
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

10.  Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals.

Authors:  Y Zhao; W You; J Zheng; Y Chi; W Tang; R Du
Journal:  Clin Transl Oncol       Date:  2016-03-04       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.